Eterna Therapeutics Inc Total Liabilities
Eterna Therapeutics Inc total liabilities. Based on the latest financial reports, Eterna Therapeutics Inc (ERNA) has total liabilities worth $3.12 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Eterna Therapeutics Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Eterna Therapeutics Inc (2006–2025)
Total liabilities of Eterna Therapeutics Inc from 2006 to 2025. This chart illustrates how Eterna Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Eterna Therapeutics Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Eterna Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Eterna Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Celtic plc
LSE:CCPA
|
UK | GBX89.90 Million |
|
Golden Goliath Resources Ltd.
V:GNG
|
Canada | CA$389.98K |
|
Fenbo Holdings Limited Ordinary Shares
NASDAQ:FEBO
|
USA | $35.80 Million |
|
Discovery Alaska Ltd
AU:DAF
|
Australia | AU$74.02K |
|
Silver Castle Holdings Ltd
TA:SLCL
|
Israel | ILA6.67 Million |
|
GRUPUL INDUSTRIAL ELECTROCONTACT S.A.
RO:ECT
|
Romania | RON932.70K |
|
BPH Global Ltd
AU:BP8
|
Australia | AU$2.26 Million |
|
Borqs Technologies Inc.
NASDAQ:BRQSF
|
USA | $29.01 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Eterna Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ERNA total asset value.
Liquidity & Leverage Metrics
Eterna Therapeutics Inc Total Liabilities Ratios Explained
Eterna Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.01 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eterna Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eterna Therapeutics Inc (2006–2025)
The table below shows the annual total liabilities of Eterna Therapeutics Inc from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.43 Million | -3.78% |
| 2024-12-31 | $3.57 Million | -92.39% |
| 2023-12-31 | $46.90 Million | +361.06% |
| 2022-12-31 | $10.17 Million | +68.94% |
| 2021-12-31 | $6.02 Million | +14.75% |
| 2020-12-31 | $5.25 Million | -48.48% |
| 2019-12-31 | $10.19 Million | +28.16% |
| 2018-12-31 | $7.95 Million | -27.98% |
| 2017-12-31 | $11.03 Million | -15.56% |
| 2016-12-31 | $13.07 Million | +0.72% |
| 2015-12-31 | $12.97 Million | +14.38% |
| 2014-12-31 | $11.34 Million | +81.36% |
| 2013-12-31 | $6.25 Million | +31.35% |
| 2012-12-31 | $4.76 Million | -10.10% |
| 2011-12-31 | $5.30 Million | +44.57% |
| 2010-12-31 | $3.66 Million | -24.90% |
| 2009-12-31 | $4.88 Million | +24.59% |
| 2008-12-31 | $3.92 Million | -26.00% |
| 2007-12-31 | $5.29 Million | -33.81% |
| 2006-12-31 | $8.00 Million | -- |
About Eterna Therapeutics Inc
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for… Read more